Evidence map›Paper›PMID 42021334›Full record

ArticleTropical medicine and health2026

Access barriers to in vitro diagnostics in Cambodia, Indonesia, Lao PDR, and the Philippines: programmatic lessons from NEDL field missions.

Shogo Kanamori, Norielyn M Evangelista, Nenita G Marayag, Richard Albert J Ramones, Sau Sokunna, Weni Muniarti, Bouaphanh Khamphaphongphane, Youthanavanh Vonghachack, Antonio F Dela Resma Villanueva, Manami Uechi and 5 more

Abstract read
In one paragraph

Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shogo KanamoriBureau of Global Health Cooperation, Japan Institute for Health Security, 1-21-2 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan. kanamori.s@jihs.go.jp.
Norielyn M EvangelistaOffice for Health Laboratories, Department of Health, San Lazaro Compound, Santa Cruz, 1003, Manila, Philippines.
Nenita G MarayagOffice for Health Laboratories, Department of Health, San Lazaro Compound, Santa Cruz, 1003, Manila, Philippines.
Richard Albert J RamonesOffice for Health Laboratories, Department of Health, San Lazaro Compound, Santa Cruz, 1003, Manila, Philippines.
Sau SokunnaDepartment of Hospital Services, Ministry of Health, Home No. 80, Samdech Penn Nouth Boulevard, Phnom Penh, Cambodia.
Weni MuniartiOffice for Directorate of Primary Healthcare Governance, Ministry of Health, Gd. Dr. Adhyatma Lantai 7 Blok C, Jl. HR. Rasuna Said Block X5 Kav. 4-9, Jakarta, 12950, Indonesia.
Bouaphanh KhamphaphongphaneNational Center for Laboratory and Epidemiology, Ministry of Health, WJM8+RG8, Vientiane, Lao PDR.
Youthanavanh VonghachackDepartment of Healthcare and Rehabilitation, Ministry of Health, XJ48+FFP, Ban Thatkhao, Sisattanack District, Rue Simeuang, Vientiane, Lao PDR.
Antonio F Dela Resma VillanuevaHealth and Social Welfare Unit, Economic Research Institute for ASEAN and East Asia, 6/f Sentral Senayan II, No. 8 Jl. Asia-Afrika, Gelora Bung Karno, Senayan, Jakarta Pusat, 10270, Indonesia.
Manami UechiHealth and Social Welfare Unit, Economic Research Institute for ASEAN and East Asia, 6/f Sentral Senayan II, No. 8 Jl. Asia-Afrika, Gelora Bung Karno, Senayan, Jakarta Pusat, 10270, Indonesia.
Yuriko EgamiBureau of Global Health Cooperation, Japan Institute for Health Security, 1-21-2 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
Naofumi HashimotoIndependent Consultant, Flat 3, No. 4 Rose Street, Salama Park, Lusaka, Zambia.
Eiichi ShimizuBureau of Global Health Cooperation, Japan Institute for Health Security, 1-21-2 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
Masataro NorizukiBureau of Global Health Cooperation, Japan Institute for Health Security, 1-21-2 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
Masami FujitaBureau of Global Health Cooperation, Japan Institute for Health Security, 1-21-2 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccess to essential in vitro diagnostics (IVDs) remains limited in many low- and middle-income countries, where persistent challenges exist in financing, human resources, infrastructure, procurement, supply chain management, and health insurance arrangements. Despite growing regional initiatives, such as the Association of Southeast Asian Nations (ASEAN) Essential Diagnostics List Initiative, country-specific evidence on barriers to IVD access remains limited. This article summarizes barriers to accessing IVDs and related lessons identified from field missions conducted as part of a technical cooperation project supporting the development of the National Essential Diagnostics Lists (NEDLs) in Cambodia, Indonesia, Lao PDR, and the Philippines.

methodsField missions were conducted in the four countries between December 2024 and May 2025. Mission reports and interview records derived from key informant interviews with government officials and health workers from ministries of health, health facilities, local health offices, and health insurance agencies were examined. Statements related to potential barriers to accessing IVDs were coded, and emergent concepts were organized into a thematic framework consisting of domains and key access barriers.

resultsSeventeen barriers to IVD access were identified across six domains (resources; procurement and supply chain; equipment maintenance; documented rules and standards; health insurance coverage; and attitudes of service recipients). Resource constraints, including limited budgets, workforce shortages, and inadequate laboratory infrastructure, were widespread. Procurement and supply chain challenges-such as weak demand forecasting, limited supplier availability, and logistical constraints-frequently resulted in stockouts. An important operational insight was that delays in health insurance reimbursement disrupted supplier payments and contributed to stockouts. Additional barriers included limited equipment maintenance capacity, gaps in guidelines and regulations, insufficient insurance coverage, and demand-side constraints such as low awareness and trust in diagnostic tests.

conclusionsAccess to IVDs in the four ASEAN countries is constrained by multifaceted health system barriers. This study highlights an underrecognized mechanism-insurance reimbursement delays leading to stockouts-that warrants policy attention in the Asian context. As countries progress from the NEDL development to implementation, the six-domain, 17-barrier framework offers a practical tool for identifying system bottlenecks and guiding targeted interventions to ensure equitable access to essential IVDs.

Indexed as

Access to healthcareDiagnosticsHealth service deliveryHealth systemsLow- and middle-income countries

Identifiers

PMID42021334
PMCPMC13104403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.